MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

93.86 2.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

93.14

Max

93.98

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+41.45% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.3B

11B

Ankstesnė atidarymo kaina

90.91

Ankstesnė uždarymo kaina

93.86

Naujienos nuotaikos

By Acuity

50%

50%

154 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-03 04:27; UTC

Svarbiausios naujienos

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026-04-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 18:30; UTC

Svarbiausios naujienos

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026-04-03 18:14; UTC

Rinkos pokalbiai

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026-04-03 17:50; UTC

Rinkos pokalbiai

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026-04-03 17:44; UTC

Įsigijimai, susijungimai, perėmimai

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026-04-03 16:50; UTC

Svarbiausios naujienos

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026-04-03 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 16:12; UTC

Uždarbis

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-04-03 15:20; UTC

Svarbiausios naujienos

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026-04-03 15:08; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026-04-03 14:11; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026-04-03 12:56; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026-04-03 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 08:01; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 08:01; UTC

Rinkos pokalbiai

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026-04-03 07:45; UTC

Rinkos pokalbiai

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026-04-03 06:17; UTC

Rinkos pokalbiai

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026-04-03 06:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 04:33; UTC

Rinkos pokalbiai

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026-04-03 04:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-03 04:01; UTC

Rinkos pokalbiai

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026-04-03 02:01; UTC

Rinkos pokalbiai

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026-04-03 01:59; UTC

Rinkos pokalbiai

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026-04-03 01:44; UTC

Rinkos pokalbiai

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026-04-03 01:22; UTC

Rinkos pokalbiai

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

41.45% į viršų

12 mėnesių prognozė

Vidutinis 132.72 USD  41.45%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

154 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat